# 2025年11月17日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 氯唑西林与头孢唑林治疗甲氧西林敏感金黄色葡萄球菌菌血症的比较（CloCeBa）：一项前瞻性、开放标签、多中心、非劣效性、随机临床试验。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41115439](https://pubmed.ncbi.nlm.nih.gov/41115439)
**期刊：** Lancet (London, England)
**PMID：** 41115439
**DOI：** 10.1016/S0140-6736(25)01624-1

### 第一部分 原文与翻译

**英文原标题：** Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.

**英文摘要原文：**
BACKGROUND: Although widely used, cefazolin efficacy for the treatment of meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia has not thus far been investigated in a clinical trial. In this study, we aimed to compare the efficacy and safety of cefazolin with that of cloxacillin in patients with MSSA bacteraemia.

METHODS: We conducted an open-label, non-inferiority, randomised clinical trial in 21 university and non-university hospitals in France in adults (aged ≥18 years) with MSSA bacteraemia, without intravascular implant or suspicion of CNS infection. Participants were randomly assigned (1:1) to receive intravenously cefazolin (25-50 mg/kg every 8 h) or cloxacillin (25-50 mg/kg every 4-6 h) for the first 7 days of therapy using computer-generated blocks of various sizes and stratification on vascular-access associated bacteraemia and centre. Subsequent treatment was left to the choice of the investigator (total duration ≥14 days). The primary endpoint was a composite of sterile blood cultures at day 3 (day 5 for endocarditis) without relapse of bacteraemia, survival, and clinical success at day 90, and was assessed in the intention-to-treat population. A non-inferiority margin of 12% was chosen. This trial is registered on ClinicalTrials.gov (NCT03248063) and is complete.

FINDINGS: Between Sept 5, 2018, and Nov 16, 2023, 315 participants were enrolled and assigned to cefazolin (n=158) or cloxacillin (n=157); 12 participants were excluded from analysis in the cefazolin group, and 11 in the cloxacillin group (final population of 146 in each group). Mean age was 62·7 years (SD 16·4), 215 (74%) participants were male, and race or ethnicity data were not collected. Median Pitt score was 0 (IQR 0-0). The primary endpoint was met in 109 (75%) of 146 participants in the cefazolin group versus 108 (74%) of 146 participants in the cloxacillin group (treatment difference -1%; 95% CI -11 to 9; p=0·012). At the end of study treatment, 22 (15%) of 146 participants assigned to cefazolin and 40 (27%) of 146 participants assigned to cloxacillin had had a serious adverse event (p=0·010). Acute kidney injury occurred more frequently in participants assigned to cloxacillin (15 [12%] of 128) than in those assigned to cefazolin (one [1%] of 134; p=0·0002).

INTERPRETATION: Cefazolin constitutes an alternative to cloxacillin for the treatment of MSSA bacteraemia, offering non-inferior clinical efficacy and potentially enhanced tolerability.

FUNDING: French Ministry of Health.

**中文摘要译文：**
背景：尽管头孢唑林被广泛用于治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症，但其疗效迄今尚未在临床试验中得到验证。本研究旨在比较头孢唑林与氯唑西林在MSSA菌血症患者中的疗效与安全性。

方法：我们在法国21家大学及非大学医院中开展了一项开放标签、非劣效性、随机临床试验，研究对象为患有MSSA菌血症的成人（年龄≥18岁），且无血管内植入物或中枢神经系统感染疑似。参与者通过计算机生成的不同大小的区组随机化，并根据血管通路相关菌血症和研究中心进行分层，以1:1的比例被分配接受静脉注射头孢唑林（每8小时25-50 mg/kg）或氯唑西林（每4-6小时25-50 mg/kg）进行为期7天的初始治疗。后续治疗方案由研究者自行决定（总疗程≥14天）。主要终点为复合终点，包括第3天（心内膜炎患者为第5天）血培养转阴且菌血症无复发、90天生存率及临床成功率，并在意向治疗人群中进行评估。非劣效性界值设定为12%。本试验已在ClinicalTrials.gov注册（NCT03248063），且已完成。

结果：在2018年9月5日至2023年11月16日期间，共招募了315名参与者，并将其分配至头孢唑林组（n=158）或氯唑西林组（n=157）；头孢唑林组有12名参与者被排除在分析之外，氯唑西林组有11名（每组最终分析人群为146人）。平均年龄为62.7岁（标准差16.4），215名（74%）参与者为男性，未收集种族或民族数据。Pitt评分中位数为0（四分位距0-0）。头孢唑林组146名参与者中有109名（75%）达到主要终点，而氯唑西林组146名参与者中有108名（74%）达到主要终点（治疗差异为-1%；95%置信区间为-11至9；p=0.012）。在研究治疗结束时，头孢唑林组146名参与者中有22名（15%）发生严重不良事件，而氯唑西林组有40名（27%）（p=0.010）。急性肾损伤在氯唑西林组（128名中的15名[12%]）比在头孢唑林组（134名中的1名[1%]）更常见（p=0.0002）。

结论：对于MSSA菌血症的治疗，头孢唑林是氯唑西林的一种替代选择，其临床疗效非劣效，且可能具有更好的耐受性。

资金来源：法国卫生部。

### 第二部分 AI 大师评价

本研究通过一项大规模、严谨的前瞻性多中心非劣效性随机临床试验，首次直接比较了头孢唑林与氯唑西林治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症的有效性与安全性。研究关键发现，头孢唑林的临床疗效不劣于传统的标准药物氯唑西林，并且在安全性上表现出显著优势，特别是显著降低了急性肾损伤的风险。这项发表于《柳叶刀》的研究为临床实践提供了高级别的循证医学证据，确立了头孢唑林作为MSSA菌血症一线治疗的可靠替代方案，有望改变临床指南并改善患者预后。

---

## 2. 社区获得性肺炎。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41110447](https://pubmed.ncbi.nlm.nih.gov/41110447)
**期刊：** Lancet (London, England)
**PMID：** 41110447
**DOI：** 10.1016/S0140-6736(25)01493-X

### 第一部分 原文与翻译

**英文原标题：** Community-acquired pneumonia.

**英文摘要原文：**
Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, including older people, immunocompromised people, those with chronic conditions, and young children. Once considered solely an acute illness, community-acquired pneumonia is now recognised as a disease with long-term complications, including cardiovascular events, respiratory impairment, and cognitive decline. Advances, such as nucleic acid amplification tests (NAATs) and the broader availability of point-of-care lung ultrasound, allow for rapid pathogen detection and personalised treatment. However, substantial uncertainties remain regarding the role of NAATs, lung ultrasounds, and serum biomarkers in clinical practice. Antibiotics are the cornerstone of community-acquired pneumonia treatment, but the roles of adjunctive therapies, including corticosteroids and immunomodulators, remain incompletely defined. Comprehensive community-acquired pneumonia management emphasises personalised treatment, rehabilitation after the acute episode, routine cardiovascular screening, and strengthening preventive measures, such as vaccination. As precision medicine advances, integrating diagnostics and tailored therapies will improve outcomes and reduce the global burden of community-acquired pneumonia.

**中文摘要译文：**
社区获得性肺炎是一项重大的全球性健康挑战，它不成比例地影响着脆弱人群，包括老年人、免疫功能低下者、慢性病患者和幼儿。社区获得性肺炎曾一度被认为仅是一种急性疾病，但现在已被认识到是一种具有长期并发症的疾病，包括心血管事件、呼吸功能损害和认知能力下降。核酸扩增试验（NAATs）和更广泛应用的即时诊断肺部超声等技术的进步，使得病原体的快速检测和个性化治疗成为可能。然而，关于NAATs、肺部超声和血清生物标志物在临床实践中的作用，仍存在着重大的不确定性。抗生素是社区获得性肺炎治疗的基石，但包括皮质类固醇和免疫调节剂在内的辅助疗法的作用尚未完全明确。社区获得性肺炎的综合管理强调个性化治疗、急性期后的康复、常规心血管筛查以及加强疫苗接种等预防措施。随着精准医学的进步，整合诊断学和定制化疗法将改善患者结局，并减轻社区获得性肺炎的全球负担。

### 第二部分 AI 大师评价

这篇发表于《柳叶刀》的综述深刻总结了社区获得性肺炎（CAP）领域的最新认知与进展。文章的核心亮点在于，它不仅将CAP的认知从一种单纯的急性病扩展为可能导致心血管事件、呼吸损伤等长期并发症的疾病，还系统性地评估了从诊断（如NAATs、肺部超声）到治疗（如抗生素、辅助疗法）的现代策略。该文通过强调个性化治疗、急性后期管理和预防的重要性，为临床医生提供了全面的指导框架，并指明了精准医学在未来优化CAP管理中的关键作用，具有极高的临床指导价值和科研启发意义。

---

速递结束，祝您工作愉快！